Your Messages Inbox
Your Article Summary
See Latest ArticlesXenoPort Announces Election of Co-Promotion Option for Solzira
XenoPort, 07/22/09
XenoPort, Inc. announced that it has exercised the option contained in its Development and Commercialization Agreement with GlaxoSmithKline (GSK) to co–promote and share profits and losses from the potential future sales of Solzira (gabapentin enacarbil) Extended Release Tablets in the United States. Solzira is the subject of a new drug application (NDA) that is under review by the U.S. Food and Drug Administration (FDA) as a potential treatment for moderate–to–severe primary Restless Legs Syndrome (RLS).
Related Articles
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Amylin Pharmaceuticals, 11/02/09
Relevance Score: 67%
Abbott to Develop New Heart Failure Test on ARCHITECT Immunochemistry Diagnostics Platform
Abbott, 11/18/09
Relevance Score: 65%
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Bristol Myers-Squibb Company, 11/11/09
Relevance Score: 65%
Morphotek, Inc. Announces a Licensing Deal with Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Morphotek, 11/03/09
Relevance Score: 65%
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Cephalon, 10/27/09
Relevance Score: 43%
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Array BioPharma and Amgen Partner in Type 2 Diabetes
Amgen, 12/15/09
Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09
Federal Advisory Committees to Meet
HealthDataManagement, 12/09/09
Article Search
Sponsor